Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses

  1. Lise L. Kjaergard, MD;
  2. John Villumsen, MSc; and
  3. Christian Gluud, MD, DrMSc
  1. From Cochrane Hepato-Biliary Group, the Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, H:S Rigshospitalet, Copenhagen, Denmark.

    Abstract

    Purpose: To explore whether reported methodologic quality affects estimated intervention effects in randomized trials and contributes to discrepancies between the results of large randomized trials and small randomized trials in meta-analyses.

    Data Sources: Meta-analyses of randomized trials that included at least one large trial (≥ 1000 participants) were included, regardless of the therapeutic area. Eligible meta-analyses were identified through electronic searches and bibliographies of relevant articles.

    Study Selection: Full-length randomized trials.

    Data Extraction: Methodologic quality was assessed according to reported randomization, double blinding, and follow-up as separate components and by using the Jadad composite scale.

    Data Synthesis: Fourteen meta-analyses involving 190 randomized trials from eight therapeutic areas were included. Compared with large trials, intervention effects were exaggerated in small trials with inadequate allocation sequence generation (ratio of odds ratios, 0.46 [95% CI, 0.25 to 0.83]; P = 0.011), inadequate allocation concealment (ratio of odds ratios, 0.49 [CI, 0.27 to 0.86]; P = 0.014), and no double blinding (ratio of odds ratios, 0.52 [CI, 0.28 to 0.96]; P = 0.01). Large trials did not differ significantly from small trials with adequate generation of the allocation sequence, adequate allocation concealment, or adequate double blinding. No association was seen between reported follow-up and intervention effects. The Jadad scale provided no additional information because the scale and the quality components overlapped substantially.

    Conclusions: Inadequate generation of the allocation sequence, allocation concealment, and double blinding lead to exaggerated estimates of intervention benefit and may contribute to discrepancies between the results of large randomized trials and small randomized trials in meta-analyses.

    Article and Author Information

    • Acknowledgments: The authors thank Doug Altman and Peter Gøtzsche for valuable comments, Nader Salasshahri for computer assistance, and Dimitrinka Nikolova for secretarial assistance.

    • Grant Support: By grants from the Danish Medical Research Council and the 1991 Pharmacy Foundation in Denmark.

    • Requests for Single Reprints: Lise L. Kjaergard, MD, Cochrane Hepato-Biliary Group, the Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, H:S Rigshospitalet, DK-2100 Copenhagen, Denmark; e-mail, kjaergard{at}ctu.rh.dk.

    • Current Author Addresses: Drs. Kjaergard and Gluud and Mr. Villumsen: Cochrane Hepato-Biliary Group, the Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, H:S Rigshospitalet, DK-2100 Copenhagen, Denmark.

    « Previous | Next Article »Table of Contents